ACIST Medical Systems, Inc., a Bracco Group company and a global leader in advanced contrast management technologies, today announced the launch in selected markets in Europe of the ACIST Pro Diagnostic System, a next-generation variable-rate contrast management solution designed to advance precision, safety and efficiency in image-guided cardiovascular procedures.

The CE Mark was granted under the European Medical Device Regulation (MDR), which confirms compliance with applicable EU safety, health, and environmental protection standards. ACIST Pro is the evolution of ACIST's automated contrast delivery technology, ACIST CVi, which revolutionised cardiac catheterisation laboratory contrast management by replacing manual injection with automated, real-time precision. Clinical use of the ACIST CVi system has demonstrated outcomes compared to manual injection, including on average 45ml reduction of contrast use, a 30 per cent reduction in CI-AKI, and an average of five minutes saved per case.

"The launch of ACIST Pro is an important step in our ongoing effort to advance precision imaging across specialities," said Dr Fulvio Renoldi Bracco, CEO of Bracco Imaging. "By thoughtfully evolving a trusted platform, we are responding to the real-world needs of today's interventional teams. This milestone reflects our commitment to delivering practical, forward-looking solutions that support quality, safety, and sustainability in diagnostic imaging."

"Building on the trusted ACIST CVi system, ACIST Pro is our next-generation solution, enhancing precision and efficiency in the cardiac catheterisation laboratory. With its European launch, we are proud to bring this advanced technology to clinicians and continue our commitment to innovation in interventional imaging," said Brad Fox, CEO of ACIST Medical Systems.